Trump announces trade deal with EU following months of negotiations
Jacob Steven Leach, the Executive Vice President and Chief Operating Officer of Dexcom Inc. (NASDAQ:DXCM), recently sold 14,076 shares of the company’s common stock. The transaction comes as Dexcom’s shares have declined 12% over the past week and 47% year-over-year. The sale, which took place on March 12, 2025, was executed at an average price of $70.38 per share, amounting to a total transaction value of approximately $990,670.
This transaction was part of a "sell to cover" arrangement, which is used to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following the transaction, Leach retains direct ownership of 313,497 shares, which includes 84,537 unvested RSUs that will vest through 2028. Additionally, 47,296 shares are held indirectly through family holdings. With a current P/E ratio of 48x and analyst targets ranging from $82 to $120, InvestingPro subscribers can access comprehensive insider trading analysis and 15+ additional investment insights for Dexcom.
In other recent news, DexCom reported its fourth-quarter earnings, which fell short of analyst expectations. The company posted adjusted earnings per share of $0.45, missing the consensus estimate of $0.52, while revenue slightly exceeded expectations at $1.11 billion, marking an 8% year-over-year increase. For the full year 2024, DexCom’s revenue rose 11% to $4.03 billion, with U.S. revenue up 10% and international revenue increasing by 15%. Looking ahead, DexCom projects 2025 revenue of approximately $4.6 billion, which is slightly below the $4.61 billion consensus forecast. The company expects a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
In other developments, DexCom recently added Renée Galá, President and COO of Jazz Pharmaceuticals (NASDAQ:JAZZ), to its Board of Directors, bringing her extensive experience in financial and strategic leadership. Meanwhile, BTIG analysts maintained a Buy rating on DexCom, with a price target of $120, even after the company received a warning letter from the FDA regarding manufacturing processes. DexCom has assured that the warning will not impact its manufacturing or financial projections. Additionally, Bernstein analysts raised their price target for DexCom shares to $100, citing a return to stability and a positive outlook for 2025 revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.